SCHEMBL4340557

SCHEMBL4340557

CN(Cc1ccc(Nc2ccccc2)cc1)CC(O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
KDM4E B2RXH2 2/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
CNR2 P34972 1/20 0.56
AOC3 Q16853 2/20 0.49
TAAR1 Q96RJ0 1/20 0.46
BCHE P06276 2/20 0.43
ACHE P22303 2/20 0.43
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 1/20 0.42
LTA4H P09960 1/20 0.41
DNM1 Q05193 1/20 0.41
NAMPT P43490 1/20 0.40
ADRB2 P07550 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343132 1.00 MEN1 (0.63) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4347718 1.00 MEN1 (0.63) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4346610 0.87 KDM4E (0.55) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL13993320 0.86 KDM4E (0.70) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL28339091 0.86 KDM4E (0.70) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL14274010 0.86 KDM4E (0.70) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4343262 0.86 MEN1 (0.57) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4348017 0.86 MEN1 (0.57) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4348629 0.83 HTT (0.52) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4352641 0.82 MEN1 (0.66) MEN1KMT2AKDM4ESMN1; SMN2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US claimed
EP-2007707-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2008-12-31 EP claimed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO claimed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
EP-2007707-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2008-12-31 EP disclosed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, OPRL1 MEN1 4775/4885KMT2A 2988/4885KDM4E 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.